2Tamsma JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann Oncol,2001;12(10):1353.
3Frank A. Scappaticci Mechanisms and future directions for angiogenesis-based cancer therapies. Journal of Clinical Oncology,2002;20(18):3906.
4Kruger EA, Duray PH, Tsokos MG, et al. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun,2000;268(1):183.
5Hitoshi Yoshiji, Shigeki Kuriyama, Daniel J.et al. The vascular endothelial growth factor receptor KDR/FIK-1 is a major regulator of malignant ascites for mation in the mouse hapatocellular carcinoma model. Hepatology,2001;33(4):841.
6O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell,1997;88(2):277.
7Noriko Yamaguchi, Bela Anand-Apte, Margaret Lee, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J,1999; 18(16):4414.
8Kyoichi Takahashi, Yoshitsugu Saishin, Yumiko Saishin, et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J,2003;17(8):896.
9Caisheng Ye, Chong Feng, Shenming Wang, et al. Antiangiogenic and Antitumor Effects of Edostatin on Follicular Thyroid Carcinoma. Endocrinology,2002;143(9):3522.
10Giannoula Klement, Sylvain Baruchel, Janusz Rak, et al. Continuous low-dose theray with vinblastine and VEGF receptor-antibody induces sustained tumor regression without overt toxicity. J Clin Invest,2000;105(8):R15.
5Kelly H, Goldberg RM. Systemic therapy for metastatic color- ectal cancer: current options, current evident[J]. J Clin Oncol, 2005, 23(20):4553-4560.
6Watanabe T, Hirono H, Hasegawa K, et al. Advanced gastric cancer patient with peritonitis carcinomatosa successfully treated with a combination therapy of paclitaxel and TS-1, but relapsed with multiple bone metastasis and died from rapidly progressive meningitis carcinomatosa advanced gastric cancer with metachro nous peritonitis carcinomatosa and meningitis carcinomatosa[J].Intern Med, 2009, 48(3):151-156.
7Erito M, Mariko S, Hideyuki S, et al. Feasibility study of post- operative intraperitoneal hyperthermochemotherapy by radiofre quency capacitive heating system for advanced gastric cancer with peritoneal seeding[J].Int J Hyperthermia, 2007,23 (6) : 493-500.
8Todd RC, Lippard ST. Inhibition of transcription by platinum antitumor compounds[J]. Metallomics, 2009, 1(14) :280-291.
9Los G, Mutsaers PHA, Vander WTF, et al. Direct diffusion of cisdiammine dichloroplatinum( Ⅱ ) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparaaion with systemic chemotherapy[J]. Cancer Res, 1989,49 (12) : 3380-3392.
10Hong JC, Sun YR, Chong KJ, et al. Docetaxel versus paclitaxel combined with 5-fu and leucovorin in advanced gastric cancer: combined analysis of two phase Ⅱ trials[J]. Cancer Res Treat, 2009, 41(4) :196-203.
